CytoNiche
a Tsinghua Medical School spin-off whose microcarriers carried the first stem-cell drug approved in China (2025) after partner 铂生卓越 switched its phase III MSC process from 2D to 3D in 2022; closed a B+ round of several hundred million RMB (2025) from Beijing municipal funds, ICBC and CICC.
- Country
- China
Growth-stage
3D TableTrix
Coverage
| CN | EU | US | |
|---|---|---|---|
| consumables | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Microcarriers for adherent cell cultures | consumables | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.